KATELYN BILLS: Open Payments
NPI 1679110456 · CINCINNATI, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$728 in 29 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $129 · 2025 $728
Food & beverage: $728
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 2 | $142 |
| Eisai Inc. | 4 | $76 |
| Novartis Pharmaceuticals Corporation | 4 | $67 |
| Gilead Sciences, Inc. | 3 | $67 |
| ABBVIE INC. | 2 | $57 |
| Adaptive Biotechnologies Corporation | 2 | $53 |
| Merck Sharp & Dohme LLC | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
Products named: JEMPERLI, Lenvima, KISQALI, clonoSEQ, KEYTRUDA, Enhertu, FRUZAQLA, Trodelvy.
Industry payments across OH — which companies pay providers there.
